During the R&D Day event, Jaume Pons, Ph.D., will introduce a new ALX Oncology (ALXO) ADC clinical candidate, ALX2004. This is a potential best- and first-in-class compound that is designed to optimize ADC-based mechanisms of anti-tumor activity and has demonstrated potent anti-tumor activity in multiple clinically relevant xenograft models. ALX Oncology intends to submit an Investigational New Drug application for ALX2004 to the U.S. Food & Drug Administration in Q1 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALXO:
- ALX Oncology will highlight progress across its clinical pipeline
- ALXO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- ALX Oncology price target lowered to $5 from $25 at H.C. Wainwright
- ALX Oncology presents updated data from ASPEN-06 Phase 2 trial
- ALX Oncology Strengthens Leadership with Key Appointments
Questions or Comments about the article? Write to editor@tipranks.com